Bibliografia
Cornell, S. (2020). A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. Journal of Clinical Pharmacy and Therapeutics, 45(Suppl 1), 17–27.
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014/2015). Adverse effects of GLP-1 receptor agonists. The Review of Diabetic Studies, 11(3–4), 202–230.
Okerson, T., & Chilton, R. J. (2012). The cardiovascular effects of GLP-1 receptor agonists. Cardiovascular Therapeutics, 30(3), e146–e155.
Prasad-Reddy, L., & Isaacs, D. (2015). A clinical review of GLP-1 receptor agonists: Efficacy and safety in diabetes and beyond. Drugs in Context, 4, 212283.
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018). Recent updates on GLP-1 agonists: Current advancements and challenges. Biomedicine & Pharmacotherapy, 108, 952–962.
Questa infografica è un’opera originale ed è distribuita con licenza Creative Commons CC BY-NCND 4.0. È consentita la diffusione con attribuzione, senza modifiche e per finalità non commerciali.
Attribuzione: © Ivan Zucconelli — CC BY-NC-ND 4.0 – www.ivanzucconelli.it
